Home New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

2015-02-25 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the companys cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11contactglove tundratracker
23.11
23.11RUSSELUNO
23.11C282 800yd IP54
23.11X-FLY4 27.5
23.118
23.11 (1~40)
23.1101DVDBOX
More »